ACEL vs HEPS

ACEL's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While the company shows strong earnings growth and beats earnings estimates consistently, high leverage (Debt/Equity: 2.22) and weak insider sentiment counterbalance these positives. Valuation is mixed—trading below analyst target of $15.17 but above the conservative Graham Number of $5.93. The stock faces headwinds from recent price underperformance and insider selling, despite solid ROE and revenue momentum.

The company exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While revenue growth remains strong at 36.9% YoY, this has failed to translate into profitability, as evidenced by a catastrophic ROE of -213.73% and a consistent track record of missing earnings estimates. Liquidity is a primary concern with a Quick Ratio of 0.59 and a Current Ratio below 1.0, suggesting an inability to meet short-term obligations. Despite a positive analyst target price, the deterministic data points to a high-risk profile with significant insolvency concerns.